Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Update

18 Jan 2012 07:00

RNS Number : 7281V
Plant Health Care PLC
18 January 2012
 



 

 

18 January 2012

 

PLANT HEALTH CARE PLC

("Plant Health Care" or "the Company")

 

Trading Update

 

Plant Health Care (AIM: PHC.L), a leading provider of naturally-derived products to the agriculture industry, provides the following post year-end update ahead of the announcement of its full year results to 31 December 2011, which are expected on 27 February 2012. All results provided are preliminary and subject to completion of the 2011 audit.

 

The Board is pleased to report that the operating loss before share-based payments is expected to be approximately $6.7 million, on revenues of $7.9 million. Due to tight control over operating costs, the operating loss was better than expectations, with revenues being slightly less than expectations. As a consequence of the lower losses and strong collections from debtors, the Company is expecting to report cash and cash equivalents at year-end of US$14 million, significantly ahead of expectations. The Company is focused on accelerating the development and improving performance of its core Harpin and Myconate technologies. As a result, R&D spend on next generation product development and formulations doubled in 2011, and is expected to increase at a similar rate in 2012 to over $1mm.

 

The Company has also been strongly focused on the pursuit of further significant partnering relationships. The following is a progress report on the most significant aspects of the business:

 

·; On-ground sales (end-user application of the product) of Harpin in the US rose approximately 40% in 2011 from programmes driven by the Company and its partners to increase market awareness and acceptance of Harpin as a critical biological enhancement to existing seed treatment options. As a result of in-hand distributor orders, we expect 2012 on-ground sales to more than triple 2011 levels. On-ground sales of Harpin have also grown rapidly in Mexico and South Africa as a result of initiatives in those markets. Both countries experienced roughly 50% growth in on-ground sales in 2011, and we expect this to accelerate by 70% in 2012.

·; As a result of the success of on-ground sales, Plant Health Care is in discussions with a number of global and regional agrichemical and agricultural supply companies to further exploit its Harpin and Myconate technologies, on new crops, by new product applications and in new geographical regions. Good progress is being made towards finalising substantial new partnering agreements during 2012.

·; 2011 delivered the best set of trial results with Harpin and Myconate that the Company has ever experienced. The strength of these results has helped escalate our partnering discussions.

·; We have developed six next generation Harpin product candidates that will be moving into initial field trials in 2012. All six candidates have exhibited significantly stronger attributes in greenhouse trials than the Harpin products that are currently in the market.

 

The Board has been greatly encouraged by the progress made in the past 12 months and believes that the increasing use of Harpin and Myconate-based products and the pipeline of potential new partnering transactions will ensure that our present cash resources will be sufficient to fund the Company through to profitability in future periods.

 

 

John Brady, Chief Executive of Plant Health Care, said: "The sale of the US retail and landscape business at the start of 2011 has allowed us to focus on obtaining licensing agreements for Harpin and Myconate and on supporting our partners in the introduction of new products. Good progress across the business and our strong trial results mean we remain confident of substantial progress and further important developments during 2012."

 

-Ends-

For further information please contact:

 

Plant Health Care plc 

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

 

Evolution Securities

Tavistock Communications

Jeremy Ellis

Jeremy Carey/Simon Compton

Tel: +44-20-7071-4300

Tel: +44-20-7920-3150

 

jeremy.ellis@evosecurities.com

 

jcarey@tavistock.co.uk

scompton@tavistock.co.uk

 

Notes to editors:

About Plant Health Care plc: Plant Health Care plc ("PHC") is a leading provider of naturally derived products for plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United States, PHC currently has approximately 40 employees and has operations in the United States, Mexico, the United Kingdom, Spain, and the Netherlands.

 

The Company's ordinary shares have been quoted on the AIM Market of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") since February 2010 (ticker symbol/ mnemonic: PHC).

 

Trademarks:

Myconate and Harpin are trademarks or trade names which Plant Health Care owns or which others own and license to Plant Health Care for use.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBUBRUVAAAAR
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.